Persephone’s mission is to unlock the potential of the gut microbiome to develop equitable precision medicine.
Why equitable precision medicine?
Cancer death rates vary significantly amongst different ethnic and racial groups.
To develop effective precision medicine for all, clinical studies are needed that accurately map disease at the population-scale, thereby reducing health disparities.
Cancer Deaths per Year*
*Per 100,000 Persons by Race/Ethnicity, both Sexes: All Cancers. www.SEER.cancer.gov
Why equitable precision medicine?
Cancer death rates vary significantly amongst different ethnic and racial groups. To develop effective precision medicine for all, clinical studies are needed that accurately map disease at the population-scale, thereby reducing health disparities.
Cancer Deaths per Year*
*Per 100,000 Persons by Race/Ethnicity, both Sexes: All Cancers. www.SEER.cancer.gov
The VOICES Study
VOICES (Vaccine Observation to Include all Communities for Equitable Science) is a non-interventional, single-site study that will enroll up to 10,000 people in the U.S. being administered any COVID-19 vaccine. The study is vaccine agnostic and will collect both blood and stool samples prior to and following subjects being vaccinated for the SARS-CoV-2 virus, with the goal of identifying and determining specific gut microbiota and the metabolic processes that are involved in optimal immune response and function. Next-generation sequencing technologies will be used to examine samples from participants who subsequently contract COVID-19 after vaccination, to accurately analyze failure data and take account of and track coronavirus variants.
The ARGONAUT Study
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 4,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of companion diagnostics to guide therapeutic decisions.
The VOICES Study
VOICES (Vaccine Observation to Include all Communities for Equitable Science) is a non-interventional, single-site study that will enroll up to 10,000 people in the U.S. being administered any COVID-19 vaccine. The study is vaccine agnostic and will collect both blood and stool samples prior to and following subjects being vaccinated for the SARS-CoV-2 virus, with the goal of identifying and determining specific gut microbiota and the metabolic processes that are involved in optimal immune response and function. Next-generation sequencing technologies will be used to examine samples from participants who subsequently contract COVID-19 after vaccination, to accurately analyze failure data and take account of and track coronavirus variants.
The ARGONAUT Study
ARGONAUT is a longitudinal, prospective, observational study that will enroll up to 4,000 advanced-stage cancer patients of diverse racial backgrounds to collect data used to develop precision microbiome medicines and for the identification of companion diagnostics to guide therapeutic decisions.
Persephone’s approach
We are leading a paradigm shift in medicine by using real-world patient data, augmented intelligence, and synthetic biology to develop equitable precision medicines for the gut microbiome.
Persephone’s approach
We are leading a paradigm shift in medicine by using real-world patient data, augmented intelligence, and synthetic biology to develop equitable precision medicines for the gut microbiome.
